Company intelligence / Profile preview

Transcription Factor Therapeutics

Reno, Nevada, United States

Ownership: Private
Development stage: Other

Overview

Transcription Factor Therapeutics (TFT) was a biotechnology company focused on developing decoy oligonucleotide therapies to modulate gene expression. Spun out from Meyer Pharmaceuticals in 2008, the company primarily focused on an NF-kappa B decoy program licensed from Anesiva (formerly Corgentech). The technology aimed to inhibit the overactivity of the NF-kappa B transcription factor, which plays a central role in inflammatory diseases and pain. Despite its early focus on these high-value targets, the company appears to have become inactive following the liquidation of its partner Anesiva in 2009.

Therapeutic areas: ImmunologyNeurology
Modalities: Synthetic oligonucleotideDecoy oligonucleotide
Industry: Biotech

Partnerships

Anesiva

Beyond the preview

Go deeper on Transcription Factor Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Transcription Factor Therapeutics.

Explore the full profile